Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Assets Average (2020 - 2025)

Historic Assets Average for Mereo BioPharma (MREO) over the last 5 years, with Q3 2025 value amounting to $58.1 million.

  • Mereo BioPharma's Assets Average fell 3712.89% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year decrease of 3712.89%. This contributed to the annual value of $71.4 million for FY2024, which is 71.09% down from last year.
  • Latest data reveals that Mereo BioPharma reported Assets Average of $58.1 million as of Q3 2025, which was down 3712.89% from $65.5 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Assets Average high stood at $186.5 million for Q4 2021, and its period low was $58.1 million during Q3 2025.
  • Its 4-year average for Assets Average is $99.8 million, with a median of $82.6 million in 2024.
  • Per our database at Business Quant, Mereo BioPharma's Assets Average skyrocketed by 6996.71% in 2021 and then crashed by 4276.58% in 2022.
  • Quarter analysis of 4 years shows Mereo BioPharma's Assets Average stood at $186.5 million in 2021, then tumbled by 42.77% to $106.7 million in 2022, then decreased by 22.64% to $82.6 million in 2024, then fell by 29.61% to $58.1 million in 2025.
  • Its last three reported values are $58.1 million in Q3 2025, $65.5 million for Q2 2025, and $72.4 million during Q1 2025.